FDA’s Critical Path Includes Anonymous Survey On Drug Development Problems
Executive Summary
FDA will be sponsoring an anonymous survey of firms to identify drug development problems as part of the agency's "Critical Path" initiative
You may also be interested in...
FDA Implementing New CMC Review Process Through Revamped Office
FDA is changing its review of chemistry, manufacturing and controls submissions with a new quality assessment office that will involve greater staff specialization
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials